期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 171, 期 5, 页码 836-844出版社
WILEY-BLACKWELL
DOI: 10.1111/bjh.13658
关键词
thrombotic microangiopathy; plasma exchange; ADAMTS13; autoimmune thrombotic thrombocytopenic purpura
类别
资金
- Luick Family Fund of the Massachusetts General Hospital
The Harvard TMA Research Collaborative is a multi-institutional registry-based effort to study thrombotic microangiopathies (TMA). Laboratory and clinical parameters were recorded for 254 cases of suspected autoimmune thrombotic thrombocytopenic purpura (TIP). Patients with severe ADAMTS13 deficiency (activity <= 10%, N = 68) were more likely to be young, female and without a history of cancer treatment or transplantation. While all patients with severe deficiency were diagnosed with autoimmune TIP, those without severe deficiency frequently had disseminated intravascular coagulation, drug-associated TMA and transplant-related TMA. Patients with severe ADAMTS13 deficiency had superior overall survival at 360 d compared to those without severe deficiency (93.0% vs. 47.5%, P < 0.0001). Almost all patients with severe deficiency received therapeutic plasma exchange (TPE), but the use of TPE in patients with ADAMTS13 activity >10% varied significantly across the institutions in our consortium (13.2-63.8%, P < 0-0001). Nevertheless, 90-d mortality was not different in patients with ADAMTS13 activity >10% between the three hospitals (P = 0-98). Our data show that patients with severe ADAMTS13 deficiency represent a clinically distinct cohort that responds well to TPE. In contrast, TMA. without severe ADAMTS13 deficiency is associated with increased mortality that may not be influenced by TPE.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据